Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.30 +0.17%

+$0.02 today

Market cap
$546.27M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.87M

Average 0.88M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$54.36M

FY 2025 · Annual

Investing Cash Flow

$2.83M

FY 2025 · Annual

Financing Cash Flow

-$21,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Depreciation & Amortization000097K
Deferred Income Tax00000
Stock-Based Compensation3.74M6.99M12.81M5.56M8.05M
Change in Working Capital(4.17M)210K3.76M1.7M(601K)
Accounts Receivables00000
Inventory00000
Accounts Payables318K(653K)(686K)(1.14M)1.56M
Other Working Capital(4.49M)863K4.45M2.84M(2.17M)
Other Non-Cash Items11.84M674K(2.05M)51.08M(2.06M)
Operating Cash Flow(36.07M)(37.37M)(20.6M)(15.56M)(54.36M)
Capital Expenditures0000(186K)
Acquisitions (Net)00000
Purchases of Investments(114.97M)(87.96M)(58.45M)(132.2M)(108.08M)
Sales of Investments0122.4M127.43M20.75M111.1M
Other Investing Activities000(9.65M)0
Investing Cash Flow(114.97M)34.44M68.98M(121.09M)2.83M
Debt Repayment00000
Common Stock Issued83.14M0841K119.75M(21K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities149K0010.98M0
Financing Cash Flow177.23M0841K130.73M(21K)
Effect of Forex Changes245K(408K)304K42K0
Net Change in Cash26.44M(3.34M)49.53M(5.88M)(51.54M)
Free Cash Flow(36.07M)(37.37M)(20.6M)(15.56M)(54.54M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$59.9M
+ D&A$97.0K
+ Stock-Based Comp$8.1M
+ Deferred Tax$0
- Working Capital-$601.0K
- Other Non-Cash-$2.1M
= Operating Cash Flow-$54.4M
- Capex-$186.0K
= Free Cash Flow-$54.5M

Analysis

FY2025 free cash flow is -$54.5M. FCF conversion is 91.1% of net income. Operating cash flow was -$54.4M, with capex of -$186.0K. The largest bridge item is Stock-Based Comp at $8.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingNov 9, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
S-3ASRS-3ASR filingNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

Does CLYM generate free cash flow?

Climb Bio, Inc. (CLYM) generated -$54.54M of free cash flow in fiscal 2025.

How much operating cash flow does CLYM produce?

Operating cash flow was -$54.36M, before capital expenditures of $186,000.00.